← Back to Search

Aromatase Inhibitor

Anastrozole for Pulmonary Arterial Hypertension (PHANTOM Trial)

Phase 2
Waitlist Available
Led By Steven M Kawut, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated with connective tissue disease, congenital heart disease, portal hypertension, or HIV infection and receiving treatment for PAH.
Most recent pulmonary function tests with FEV1/FVC >50% AND either a) total lung capacity > 70% predicted or b) total lung capacity between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months, 6months,12 months
Awards & highlights

PHANTOM Trial Summary

This trial is testing whether the drug anastrozole can improve walking distance in people with pulmonary arterial hypertension, and whether it is safe to use for up to twelve months.

Eligible Conditions
  • Pulmonary Arterial Hypertension

PHANTOM Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PHANTOM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months, 6months,12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months, 6months,12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Difference in changes in SF36 between anastrozole and placebo groups
Difference in changes in actigraphy-measured physical activity between anastrozole and placebo groups
Difference in changes in biomarkers between anastrozole and placebo groups
+7 more

Side effects data

From 2018 Phase 4 trial • 79 Patients • NCT02137538
10%
Fracture
8%
Acne
5%
Scoliosis
3%
Hair loss
3%
Sacroiliitis
3%
Neuro event
100%
80%
60%
40%
20%
0%
Study treatment Arm
Anastrozole
Letrozole

PHANTOM Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AnastrozoleExperimental Treatment1 Intervention
1mg (1 tablet)taken by mouth once a day for one year
Group II: PlaceboPlacebo Group1 Intervention
1 tablet taken by mouth once a day for one year
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Anastrozole
2019
Completed Phase 4
~10090

Find a Location

Who is running the clinical trial?

Rhode Island HospitalOTHER
260 Previous Clinical Trials
71,650 Total Patients Enrolled
2 Trials studying Pulmonary Arterial Hypertension
25 Patients Enrolled for Pulmonary Arterial Hypertension
Vanderbilt UniversityOTHER
703 Previous Clinical Trials
6,142,885 Total Patients Enrolled
5 Trials studying Pulmonary Arterial Hypertension
1,224 Patients Enrolled for Pulmonary Arterial Hypertension
Washington University School of MedicineOTHER
1,928 Previous Clinical Trials
2,296,880 Total Patients Enrolled
1 Trials studying Pulmonary Arterial Hypertension

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~12 spots leftby Mar 2025